MicroRNA‑124 expression in the brains of rats during early cerebral ischemia and reperfusion injury is associated with cell apoptosis involving STAT3
- Authors:
- Published online on: January 30, 2019 https://doi.org/10.3892/etm.2019.7220
- Pages: 2870-2876
Abstract
Introduction
Cerebral ischemia, which results from the occlusion of an artery in brain, is a leading cause of morbidity and mortality in adults all over the world (1). During ischemia and the subsequent condition, reperfusion, the decline of cerebral blood flow leads to the deprivation of oxygen and glucose, and determines the severity of the ischemic insult (2). An ischemic insult is an area where there is a complete absence of blood flow and neuronal death occurs. Around the insult is an ischemic penumbra, in this area blood flow is reduced and function is impaired, however metabolism remains active (3). If blood flow is not restored in a short time, the neurons in the penumbra enter apoptosis (4). Traditionally, necrosis is considered the major cell death pathway in cerebral ischemia, but studies in the past decades have revealed that in the first few hours after ischemia neurons in the ischemic penumbra transiently undergo reversible damage and ultimately apoptosis (2,5). Although the duration of ischemia is a crucial factor of brain tissue damage, subsequent reperfusion also serves a prominent role in the acceleration of irreversible damage (6). Therefore, the initial few hours of reversible neuronal injury provides an opportunity for therapeutic intervention (2).
MicroRNAs are small non-coding RNAs 18–25 nucleotides in length, which can bind to the 3′-untranslated region of mRNAs to achieve downregulation of the target mRNA via degradation or translational inhibition (7). Previous studies have demonstrated that microRNAs served a role in the therapy of cerebral ischemia and reperfusion injury (8–10). In response to cerebral ischemia, microRNA expression was dynamic; among these microRNAs, microRNA-124 was expressed at high levels in the central nervous system (7). MicroRNA-124 protected neurons against cerebral ischemia through multiple molecular mechanisms (11–13) and showed promising therapeutic potential for the treatment of central nervous system diseases (14). In addition, microRNA-124 possessed anti-cancer effects (15–17) and was hepatoprotective (18). To better understand cerebral ischemia and reperfusion injury, and how to provide effective therapeutic intervention, the present study examined the changes in microRNA-124 expression in the brain tissue of rats during early ischemia and reperfusion. The tissue was examined at different time points and the association with cell apoptosis involving STAT3 activation was investigated.
Materials and methods
Chemicals and reagents
Water was prepared from water distilled by Millipore Milli-Q® system (EMD Millipore, Billerica, MA, USA). Antibodies directed against apoptosis regulator Bcl-2 (Bcl-2; cat. no. 610538) were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Anti-apoptosis regulator Bax (Bax; cat. no. AF0120), -caspase-3 (cat. no. AF7022) and -β-tubulin (cat. no. T0023) antibodies were obtained from Affinity Biosciences (Cincinnati, OH, USA). The total RNA extraction kit and microRNA-124 reverse transcription-quantitative polymerase chain reaction (RT-qPCR) kit were supplied by Suzhou Jima Gene Co. Ltd. (Suzhou, China). Anti-signal transducer and activator of transcription 3 (STAT3; cat. no. ARH4012) and -phosphorylated (p-)STAT3 (cat. no. ARE6058) antibodies were purchased from AR Biosciences USA, Inc. (San Diego, CA, USA).
Animals
A total of 54 male Sprague Dawley rats (250–280 g, 8.0±0.5 weeks) were supplied by the Experimental Animals Center of North China University of Science and Technology (Tangshan, China). The animals were housed in controlled conditions (temperature, 23±2°C; humidity, 45–60%; 12 h light/dark cycle; free access to water and a standard diet). All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals guidelines (National Institutes of Health, Bethesda, MD, USA) (19), with the approval of the Animal Care and Use Committee of North China University of Science and Technology.
Middle cerebral artery occlusion (MCAO)
The rats were subjected to MCAO, as previous description (20). Briefly, the rats were anesthetized with 10% chloral hydrate [350 mg/kg, intraperitoneal injection (IP)]. The internal, external and right common carotid arteries were exposed surgically. A 3600AAA monofilament nylon suture (Guangzhou Jialing Biotech Co., Ltd., Guangzhou, China) was inserted into the internal carotid artery through the external carotid artery stump and the MCA was occluded. To ensure MCAO caused ischemia, the rats above grade 2 in neurologic examination were considered successful models, as previously described (21). After 2 h of MCAO, the suture was removed to restore blood flow. At certain time points (3, 6, 12 and 24 h after reperfusion), the rats were sacrificed under anesthesia [10% chloral hydrate (350 mg/kg, IP)] by decapitation to get the brain tissue on ice as previously described (22). The brain tissue was stored under −80°C until they were analyzed. The rats in the sham group underwent the same surgery after 3 h, but the MCA was not occluded.
RNA extraction and RT-qPCR analysis
The total RNA was extracted from the brain tissue by a single-step method using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to manufacturer's protocol. The concentration and integrity of RNA were determined by Hairpin-it™ miRNA qPCR Quantitation kit (cat. no. QPM-012; Suzhou GenePharma Co., Ltd., Suzhou, China) according to the manufacturer's protocol. An RT-qPCR analysis was performed on the iQ™5 Real-Time PCR system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) under following conditions: 95°C for 3 min, and 40 cycles of 95°C for 12 sec and 62°C for 40 sec. Primers for microRNA-124 and U6 were supplied in the Hairpin-it™ miRNA qPCR Quantitation kit. The microRNA-124 and U6, the internal control, were detected using a U6 real time RT-qPCR normalization kit (Suzhou GenePharma Co., Ltd.) according to the manufacturer's protocol. The relative quantification value for the target gene was calculated using the 2−ΔΔCq method (23).
Immunohistochemical analysis
At the aforementioned time points, the rats were sacrificed by decapitation under deep anesthesia with 10% chloral hydrate (350 mg/kg, IP), then perfused with 10% paraformaldehyde at room temperature for 10 min and washed with saline. The whole brain was removed and immersed in 10% paraformaldehyde for 24 h at 4°C. The tissues were rinsed with PBS, dehydrated through gradients of alcohol and xylene, and then embedded in paraffin. Brain sections (5-µm-thick) were prepared on the RM2245 Semi-Automated Rotary Microtome (Leica Microsystems GmbH, Wetzlar, Germany). The sections was rehydrated in descending alcohol series at room temperature. The antigen retrieval was implemented in 0.01 M citrate buffer solution in an autoclave at 95°C for 1 min. The sections were cooled to room temperature and washed with PBS three times. Then the sections were incubated in 3% H2O2 for 15 min to block endogenous peroxidase and subsequently washed with 0.01 M PBS three times for 3 min each time. Then the sections were blocked in buffer with 10% goat serum from a SPlink detection kit (cat. no. AR100089; OriGene Technologies, Inc., Beijing, China) at room temperature for 15 min. Caspase-3, Bcl-2 and Bax primary antibodies (1:500 dilution) were added to the sections and incubated overnight at 4°C. The sections were washed with 0.01 M PBS for 3 min again. Then the goat anti-rat immunoglobulin (Ig)G secondary antibodies conjugated to biotin from the SPlink detection kit were applied and incubated at room temperature for 15 min followed by the addition of an avidin-biotin-horseradish peroxidase complex solution from the SPlink detection kit at room temperature for another 15 min. The sections were treated with 3,3′-Diaminobenzidine tetrahydrochloride as the color substrate at room temperature for 5 min. Then the sections were rinsed with water and stained by hematoxylin at room temperature for 5 min. The labeled sections were examined under an inverted optical microscope at a magnification of ×400. With the exception of the incubation of the primary antibodies, the procedure was the same for the control groups.
Western blot analysis
Western blot analyses were employed to determine the expression of cleaved caspase-3, Bcl-2, Bax, STAT3 and p-STAT3. In short, total protein was extracted using Whole Cell Lysis Assay kit (cat. no. KGP2100; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) from brain tissue and quantified by a bicinchoninic acid assay kit according to the manufacturer's protocol. Then the samples (30 µg/lane) were denatured at 95°C for 30 min and separated by SDS-PAGE on a 15% gel. The samples were then transferred to polyvinylidene difluoride membranes. Following blocking of the membranes with 5% skimmed milk at 37°C for 1 h, the membranes were incubated overnight with anti-caspase-3, -Bcl-2, -Bax, -STAT3, -p-STAT3 and -β-tubulin primary antibodies (1:1,000 dilution) at 4°C. The goat anti-rat IgG secondary antibodies conjugated to horseradish peroxidase (1:1,000 dilution; cat no. A0192; Beyotime Institute of Biotechnology, Shanghai, China) were added and incubated at room temperature for 2 h. The results were detected by enhance chemiluminescence substrate (cat no. P0018; Beyotime Institute of Biotechnology) on Azure c300 Chemiluminescent Western Blot Imaging System (Azure Biosystems, Inc., Dublin, CA, USA). β-tubulin (1:1,000 dilution) was used as the internal control. Densitometric analysis was performed by ImageJ software (version 1.5; National Institutes of Health) to obtain the relative intensities of the bands.
Statistical analysis
All results are expressed as mean ± standard deviation. GraphPad Prism software (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA) analyzed the results. Statistical differences were compared by one-way analysis of variance followed by Dunnett's test for comparisons between multiple groups and Student's t-test for comparisons between two groups. P<0.05 was considered to indicate a statistically significant difference.
Results
MicroRNA-124 expression increases in ischemic brain tissue in the 12 h after reperfusion
The expression of microRNA-124 in the sham group was similar to that of the control group (Fig. 1). However, 3 h after reperfusion, compared with the sham group, the expression of microRNA-124 in the brain tissue of experimental rats was significantly elevated at 2.74±0.32. Then at the 6 h time point, the expression reached 4.70±0.62, which was significant increased compared with the 3 h treatment group. MicroRNA-124 expression at the 12 h time point was ~6 times that of the control group at 6.77±0.67, which was a significant increase compared with the 6 h treatment group. At 24 h, the expression of microRNA-124 was 5.30±0.76, which was similar to the 6 h and significantly reduced compared with the 12 h treatment group. These results demonstrate that microRNA-124 expression is dynamic following reperfusion and neuronal injury.
Caspase-3 expression increases in ischemic brain tissue in the 24 h after MCAO and reperfusion
As a member of the cysteine-dependent aspartate-directed protease family, caspase-3 is an effector enzyme involved in cell apoptosis (24). An immunohistochemical analysis revealed that the expression of caspase-3 was upregulated following MCAO and reperfusion, although the expression of caspase-3 was not evident in the control group (Fig. 2). Western blotting confirmed the aforementioned results and gave a profile of caspase-3 expression in relative levels (Fig. 3). Following a densitometric analysis, caspase-3 expression was identified to be significantly upregulated 3 h after MCAO and reperfusion (0.49±0.01) compared with the sham group; the expression level of caspase-3 continued to increase significantly 24 h after reperfusion (0.91±0.01; Fig. 4) compared with the 12 h treatment group. These results demonstrate that neuronal apoptosis follows MCAO and reperfusion, and that the injury worsens with time at the early stage of cerebral ischemia and reperfusion.
Bcl-2 and Bax exhibit similar expression levels in ischemic brain tissue as their expression increases following MCAO and reperfusion
An immunohistochemical analysis revealed the dynamic expression of Bcl-2 and Bax following MCAO and reperfusion. The expression of Bax increased similarly to caspase-3 following MCAO and reperfusion (Fig. 5). By contrast, Bcl-2 expression increased and peaked 12 h after MCAO and reperfusion (Fig. 6), which was in accordance with the dynamic changes of microRNA-124. Western blotting confirmed these results (Fig. 3) and the densitometric analysis of the relative levels of Bcl-2 and Bax supported the results quantitatively (Fig. 7A). Bcl-2 and Bax were significantly upregulated at the 3, 6, 12 and 24 h time points compared with the sham group and, 3, 6 and 12 h treatment groups, respectively. Additionally, the relative ratio of Bcl-2 and Bax demonstrated that the protein expression increased following MCAO and reperfusion, peaked at 12 h, and then decreased (Fig. 7B).
STAT3 and p-STAT3 exhibit opposing expression profiles, with p-STAT3 expression increasing following MCAO and reperfusion in ischemic brain tissue
To investigate the involvement of STAT3 in cerebral ischemia and reperfusion, STAT3 and p-STAT3 were analyzed by western blotting and western blot analysis. No significant differences in the expression of STAT3 and p-STAT3 were identified between the control group and the sham group, although p-STAT3 expression was low (Figs. 3 and 8). Following MCAO and reperfusion, STAT3 was activated through phosphorylation, which led to a significant upregulation of p-STAT3 at 3 h compared with the sham group. Following MCAO and reperfusion, p-STAT3 expression peaked at 12 h, which was significantly greater compared with the expression at 6 h, then significantly declined at the 24 h time point. Accordingly, compared with the sham group, STAT3 was significantly reduced after 3 h of MCAO and reperfusion, and after 12 h STAT3 expression reached its minimum level, which was significantly reduced compared with the expression at 6 h. At the 24 h time point, STAT3 expression was significantly upregulated compared with the 12 h treatment group. These results were consistent with the dynamic expression of Bcl-2 and microRNA-124, thus an association between STAT3, Bcl-2 and microRNA-124 was indicated.
Discussion
Cerebral ischemia and reperfusion injury results from a deficiency in cerebral blood flow, as well as subsequent oxygen and glucose deprivation, and restoration (2). Apoptosis contributes largely to cell death in cerebral ischemia and reperfusion injury (2). As a microRNA specifically expressed in brain tissue, microRNA-124 can protect cells from apoptosis in cerebral ischemic areas (11). The results of the present study demonstrated that the expression of microRNA-124 in brain tissue was dynamic during the early stage of cerebral ischemia and reperfusion injury, and the level of microRNA-124 expression peaked at the 12 h time point. This result supports the hypothesis that microRNA-124 attenuates the injury induced by cerebral ischemia and reperfusion during the early stage.
Caspase-3 is a member of the cysteine-dependent aspartate-directed protease family and was revealed to drive the mitochondria- and death receptor-mediated signaling pathways in apoptosis (25). Caspase-3 is activated through the cleavage of pro-caspase-3, the cleaved caspase-3 served a role in mitochondria-mediated apoptosis (3). Bcl-2 and Bax are members of the Bcl-2 protein family, which regulates various cellular activities (26). Bcl-2 and Bax were also involved in cerebral ischemia through the modulation of mitochondria-mediated apoptosis (2). Bcl-2 exhibits an anti-apoptotic effect and inhibits the activation of caspase-3 while Bax demonstrates a pro-apoptotic effect (27). In addition, Bax can dimerize, dimerized Bax initiates the activation of terminal caspases, which results in the promotion of apoptosis (27). Conversely, the heterodimer of Bcl-2/Bax prevents certain downstream events in apoptosis (26). In the present study, the expression of caspase-3 and Bax increased during the early stage of cerebral ischemia and reperfusion, which indicated that the injury was being exacerbated. On the contrary, the expression of Bcl-2 increased prior to the injury and reached peak expression at the 12 h time point, following by a decrease. Accordingly, the ratio of Bcl-2/Bax was highest 12 h after MCAO and reperfusion. These results were consistent with the dynamic expression of microRNA-124, which implies that Bcl-2 is involved in the protection of the brain against cerebral ischemia and reperfusion injury, and that caspase-3 and Bax are promoters of that injury.
STAT3 serves an important role in the regulation of cell apoptosis. STAT3, an inactive protein, can be activated through phosphorylation upon neural injury to exert a protective effect (28). p-STAT3 is involved in the tyrosine-protein kinase JAK (JAK)2/STAT3 signaling pathway to promote cell viability (29) and protect the brain against cerebral ischemia injury (30). As the substrate of STAT3, Bcl-2 was regulated by p-STAT3 during cerebral ischemia (31). The present study determined that the expression of p-STAT3 was upregulated and peaked 12 h after MCAO and reperfusion, and then the expression decreased. Accordingly, the expression of STAT3 was downregulated and its lowest level was at the 12 h time point. This trend mirrored microRNA-124 and Bcl-2 expression, which suggests that STAT3 is associated with Bcl-2.
In conclusion, the present study elucidated the dynamic expression of microRNA-124 during the early stage of cerebral ischemia and reperfusion. Anti-apoptotic proteins, including Bcl-2, STAT3 and p-STAT3 exhibit similar changes in their expression, synchronous with microRNA-124, protecting brain tissue from injury. Pro-apoptotic proteins, including caspase-3 and Bax, were consistently upregulated following reperfusion. This present study reveals that the protective effect of microRNA-124 is associated with Bcl-2 and involved in the JAK2/STAT3 signaling pathway. This gives insight into the possible diagnosis of and therapy for cerebral ischemia and reperfusion injury.
Acknowledgements
Not applicable.
Funding
No funding was received.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Authors' contributions
WZ designed the study, performed the collection, analysis and interpretation of data, and wrote the manuscript. AM designed the study, performed the analysis and interpretation of data, and revised this manuscript.
Ethics approval and consent to participate
The current study was approved by the Animal Care and Use Committee of North China University of Science and Technology (Tangshan, China).
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
|
Flynn RW, MacWalter RS and Doney AS: The cost of cerebral ischemia. Neuropharmacology. 55:250–256. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mehta SL, Manhas N and Raghubir R: Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev. 54:34–66. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ji HJ, Wang DM, Hu JF, Sun MN, Li G, Li ZP, Wu DH, Liu G and Chen NH: IMM-H004, a novel courmarin derivative, protects against oxygen- and glucose-deprivation/restoration-induced apoptosis in PC12cells. Eur J Pharmacol. 723:259–266. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Endres M, Engelhardt B, Koistinaho J, Lindvall O, Meairs S, Mohr JP, Planas A, Rothwell N, Schwaninger M, Schwab ME, et al: Improving outcome after stroke: Overcoming the translational roadblock. Cerebrovasc Dis. 25:268–278. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu DM, Wang ZH, Liu L, Zhang XM and Lou FL: Acetylpuerarin increases cell viability and reduces apoptosis in rat hippocampal neurons following oxygen-glucose deprivation/reperfusion. Mol Med Rep. 8:1453–1459. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li D, Shao Z, Vanden Hoek TL and Brorson JR: Reperfusion accelerates acute neuronal death induced by simulated ischemia. Exp Neurol. 206:280–287. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Di Y, Lei Y, Yu F, Changfeng F, Song W and Xuming M: MicroRNAs expression and function in cerebral ischemia reperfusion injury. J Mol Neurosci. 53:242–250. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Deng H, Xu S and Zhang J: MicroRNAs regulate mitochondrial function in cerebral ischemia-reperfusion injury. Int J Mol Sci. 16:24895–24917. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Min XL, Wang TY, Cao Y, Liu J, Li JT and Wang TH: MicroRNAs: A novel promising therapeutic target for cerebral ischemia/reperfusion injury. Neural Regen Res. 10:1799–1808. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fasanaro P, Greco S, Ivan M, Capogrossi MC and Martelli F: MicroRNA: Emerging therapeutic targets in acute ischemic diseases. Pharmacol Therape. 125:92–104. 2010. View Article : Google Scholar | |
|
Sun Y, Gui H, Li Q, Luo ZM, Zheng MJ, Duan JL and Liu X: MicroRNA-124 protects neurons against apoptosis in cerebral ischemic stroke. CNS Neurosci Ther. 19:813–819. 2013.PubMed/NCBI | |
|
Liu X, Li F, Zhao S, Luo Y, Kang J, Zhao H, Yan F, Li S and Ji X: MicroRNA-124-mediated regulation of inhibitory member of apoptosis-stimulating protein of p53 family in experimental stroke. Stroke. 44:1973–1980. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Doeppner TR, Doehring M, Bretschneider E, Zechariah A, Kaltwasser B, Müller B, Koch JC, Bähr M, Hermann DM and Michel U: MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation. Acta Neuropathol. 126:251–265. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Luo ZM, Guo XM, Su DF and Liu X: An updated role of microRNA-124 in central nervous system disorders: A review. Front Cellular Neurosci. 9:1932015. View Article : Google Scholar | |
|
Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama K, et al: MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. Cancer Lett. 363:17–27. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Ai X, Shen S and Lu S: NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget. 6:8244–8254. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xi ZW, Xin SY, Zhou LQ, Yuan HX, Wang Q and Chen KX: Downregulation of rho-associated protein kinase 1 by miR-124 in colorectal cancer. World J Gastroenterol. 21:5454–5464. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Yi S, Deng Y, Cheng J, Wu X, Liu W, Tai Y, Chen G, Zhang Q and Yang Y: MiR-124 protects human hepatic L02 cells from H2O2-induced apoptosis by targeting Rab38 gene. Biochem Biophys Res Commun. 450:148–153. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kwiatkowski K, Piotrowska A, Rojewska E, Makuch W and Mika J: The RS504393 influences the level of nociceptive factors and enhances opioid analgesic potency in neuropathic rats. J Neuroimmune Pharmacol. 12:402–419. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Longa EZ, Weinstein PR, Carlson S and Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:84–91. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL and Bartkowski H: Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke. 17:472–476. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Jia D, Han B, Yang S and Zhao J: Anemonin alleviates nerve injury after cerebral ischemia and reperfusion (I/R) in rats by improving antioxidant activities and inhibiting apoptosis pathway. J Mol Neurosci. 53:271–279. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 5:897–907. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu JR, Tao YF, Lou S and Wu ZM: Protective effects of ginsenoside Rb3 on oxygen and glucose deprivation-induced ischemic injury in PC12 cells. Acta Pharmacol Sin. 31:273–280. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Murphy KM, Ranganathan V, Farnsworth ML, Kavallaris M and Lock RB: Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. Cell Death Differ. 7:102–111. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Youle RJ and Strasser A: The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou H, Zhang Z, Wei H, Wang F, Guo F, Gao Z, Marsicano G, Wang Q and Xiong L: Activation of STAT3 is involved in neuroprotection by electroacupuncture pretreatment via cannabinoid CB1 receptors in rats. Brain Res. 1529:154–164. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Y, Cai B, Xue XH, Fang L, Wu ZY and Wang N: TAT-mediated delivery of neuroglobin attenuates apoptosis induced by oxygen–glucose deprivation via the Jak2/Stat3 pathway in vitro. Neurol Res. 37:531–538. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Li H and Li M: Curcumin protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway in rats. Int J Clin Exp Med. 8:14985–14991. 2015.PubMed/NCBI | |
|
Shyu WC, Lin SZ, Chiang MF, Chen DC, Su CY, Wang HJ, Liu RS, Tsai CH and Li H: Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. J Clin Invest. 118:133–148. 2008. View Article : Google Scholar : PubMed/NCBI |
